ImaginAb, the market leader in developing next generation immuno-oncology imaging agents and an emerging player in the field of radiopharmaceutical therapy (RPT) is hosting a Breakfast Symposia at the SNMMI 2022 Annual Meeting in Vancouver.
During the session, expert panel members will present and discuss its Phase I data, while also looking at current clinical data from its Phase IIa trial and provide details of ImaginAb’s currently recruiting Phase IIb ‘iPREDICT’ trial. This trial aims to assess ‘predictive’ performance, with its primary objective to evaluate the performance of 89Zr-Df-crefmirlimab positron emission tomography/computed tomography (PET/CT) for predicting patient response to immunotherapy. The trial builds on the data from the company’s Phase IIa ‘BOT’ (Baseline On/Treatment) Trial, which completed enrollment last November
In addition, Pfizer (one of ImaginAb’s consortium members) will present pre-clinical study data and outline how it designs clinical trials using CD8 imaging.
6.45 - 6.50 am (PST) |
Welcome and introduction to ImaginAb & zirconium 89 crefmirlimab berdoxam |
Dr. Ian WilsonPresident & CEO - ImaginAb |
6.50 - 7.00 am (PST) |
CD8 PET Imaging of tumor infiltrating T cells in advanced solid tumors. A phase 1 first-in-human study of zirconium Zr 89 crefmirlimab berdoxam –– a radiolabeled anti-CD8 Minibody |
Michael Farwell, M.D.Assistant Professor of Radiology - University of Pennsylvania |
7.00 - 7.10 am (PST) |
An early look at immune responsesSummary of ImaginAb’s Phase IIa trial and a review of Phase IIb iPREDICT study |
Kim Margolin, M.D, FASCOMedical Director, Melanoma Program, St John's Cancer Institute |
7.10 - 7.20 am (PST) |
CD8 PET Imaging (89Zr-Df-crefmirlimab) in drug development, with decision making capabilitiesHow Pfizer designs their clinical trials with CD8 Imaging |
Dr. Kevin MarescaHead of PET & Molecular Imaging, Early Clinical Development Group - Pfizer |
7.20 - 7.40 am (PST) |
Q&A Session |
Speakers andPanel MembersProf. Andrew Scott - Olivia Newton John Cancer Center/Austin HealthAnna Wu - City of Hope/ImaginAbDr. Ian Wilson |
7.40 - 7.45 am (PST) |
Conclusion and meeting close |
Dr. Ian Wilson |
We are available to connect with conference delegates throughout the meeting June 11th - June 14th
If you have any questions or want information on its investigational agent zirconium 89-Df crefmirlimab berdoxam then please stop at our booth where our team would be delighted to meet and talk.
Poster presentations will be available after presentation on the Knowledge Hub, sign up by clicking here: Knowledge Hub
Follow us on social media: ImaginAb's Linked In
President & CEO of ImaginAb
With over 25 years of experience in development of in vivo medical diagnostics and imaging medical devices, he is a highly established and influential member of the industry and has built an enviable skill-set over the years through a number of significant healthcare roles.
It’s this diverse portfolio of skills, along with his aspirational vision of growing ImaginAb to transform the healthcare and biotechnology industry that has led Dr. Wilson to accelerate ImaginAb’s business presence and performance.
Assistant Professor of Radiology at the University of Pennsylvania.
Dr. Michael Farwell received his MD from Columbia University, is board-certified in Diagnostic Radiology and Nuclear Medicine, and he holds a master’s degree in Organic Chemistry from Harvard University. Dr. Farwell runs a translational research laboratory that is focused on oncologic applications of molecular imaging, including (1) the development of new methods for tracking CAR T cells and other cellular therapies, and (2) the development of new imaging probes to assess the immune response via PET.
Dr. Farwell serves as Principal Investigator on several clinical trials that utilize imaging biomarkers to guide more effective individualized treatment for cancer, including a trial to evaluate if an early tumor “flare” on FDG PET/CT predicts response to anti-PD-1 therapy. In addition, Dr. Farwell is the Imaging Lead for a multicenter Phase 2 PET/CT imaging trial that employs a 89Zr-labeled anti-CD8 minibody (89Zr-Df-Crefmirlimab) to image CD8+ T cells in patients receiving cancer immunotherapy.
Dr. Farwell is co-Chair of the ECOG-ACRIN Immuno-Oncology Working Group and he is the Imaging Chair of the ECOG-ACRIN Melanoma Committee.
Medical Director, Melanoma Program, St John's Cancer Institute
Dr. Margolin specializes in melanoma and other skin cancers with a focus on immunotherapy. She came to Providence/St. John’s from the City of Hope, where she worked for a total of 30 years, stopping out for 6 years at University of Washington/Seattle Cancer Care Alliance and 1 year at Stanford’s Department of Medical Oncology.
Dr. Margolin has co-led the Cytokine Working Group and the Cancer Immunotherapy Trials Network, participated in SWOG’s Melanoma Committee, and served ASCO and the Society for Immunotherapy of Cancer in many capacities. She has served on the FDA’s Oncology Drugs Advisory Committee and has been on two advisory committees to the European Organization for the Research and Treatment of Cancer.
Among her research interests are brain metastasis in melanoma and immunotherapy of skin cancers. Dr. Margolin will collaborate with surgeons and laboratory investigators at St. John’s and will lead the institute’s efforts in therapeutic trials for advanced melanoma and other cutaneous cancers.
Head of PET & Molecular Imaging, Early Clinical Development Group - Pfizer
The PET and Molecular Imaging Group serves across all Pfizer therapeutic areas, with a broad scope that includes novel preclinical ideas to POC and late phase clinical trials. The model employed utilizes key collaborations to mainly outsource data generation for preclinical and clinical studies, using both routine and novel methodology. Dr. Maresca is a multi-faceted PET Imaging scientist with more than 20 years of pharmaceutical drug discovery and development experience in the area of targeted small molecules, peptides, and biologic-based drug product candidates, with over 50 publications and 10 patents.
Kevin joined Pfizer from Molecular Insights Pharmaceuticals (Cambridge, MA) where he worked for 14 years, having served as Director of Radiochemistry and Production. Overall, he has been involved with the advancement of >15 radiolabeled compounds into clinical trials, including the development and optimization of the drug product 99mTc-MIP-1404, a potent prostate specific membrane antigen (PSMA) inhibitor for the diagnostic imaging of metastatic prostate cancer. Kevin received his PhD in Chemistry from Syracuse University, and was a Postdoctoral Fellow at Harvard Medical School, Brigham and Woman’s Hospital.
Prof. Andrew Scott leads the Tumour Targeting Program at the Olivia Newton-John Cancer Research Institute and co-Director, Centre for Research Excellence in Brain Tumours; is Director, Department of Molecular Imaging and Therapy, Austin Health; and is Professor, University of Melbourne and La Trobe University. His clinical and research interests are focused on developing innovative strategies for targeted therapy of cancer (particularly with monoclonal antibodies), molecular imaging in oncology, and global advocacy in Oncology and Nuclear Medicine. His laboratory has been involved in the preclinical development and first-in-man trials of numerous recombinant antibodies in cancer patients, and seven antibodies developed in his laboratory have been licenced to Biotech and Pharma companies, and have entered Phase I/II/III trials. He has published 411 peer reviewed papers and 27 book chapters, is an inventor on 24 patents, and is a founder of two biotech companies.
Anna M. Wu, Ph.D., is professor and chair of the Department of Immunology and Theranostics, co-director, Center for Theranostics Studies and professor in the Department of Radiation Oncology at City of Hope in Duarte, California.
Anna’s research interests include engineered antibodies and proteins for targeting, imagining, and therapeutic approaches in cancer and immunology, including the use of SPECT, PET, optical, and multimodality approaches.
Dr. Wu also holds the title of research professor, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, where she previously served as professor and vice chair. While at UCLA, she also held positions as director, Cancer Molecular Imaging Program, Jonsson Comprehensive Cancer Centre, and co-associate director, Crump Institute for Molecular Imaging. She is a past chair of the California Breast Cancer Research Council, and fellow and past president of the World Molecular Imaging Society.
Anna is the co-founder and chief scientific advisor to ImaginAb. She began her independent research career as an assistant research scientist at Beckman Research Institute of City of Hope and advanced to the position of professor of molecular biology in 2002.
Dr. Wu received her A.B. degree in biochemical sciences from Harvard University and a Ph.D. from Yale University in molecular biophysics and biochemistry (MB&B). Postdoctoral studies were conducted at Yale University (MB&B) and at University of California San Francisco in the Department of Biochemistry and Biophysics.
